Analyst consensus rating

Kalaris Therapeutics Analyst Rating: Strong Buy

Direct answer

Kalaris Therapeutics's consensus rating is Strong Buy.

6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $16.33.
Forecast evidence checked November 21, 2026.

Get free Kalaris Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$1.28
Average price target
$16.33
High price target
$23.00
Low price target
$4.00
Low target gap
+212.5%
Target upside
+1,176%
High target gap
+1,696.9%
Target range width
1,484.4%
Consensus rating
Strong Buy
Analysts
6
Evidence date
November 21, 2026
Valid through
November 28, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Kalaris Therapeutics?

Kalaris Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $16.33.

How far are Kalaris Therapeutics's low and high targets from the recorded price?

The low target implies +212.5%, while the high target implies +1,696.9%.

How many analysts are included in Kalaris Therapeutics's consensus?

The verified consensus includes 6 analysts.

How is Kalaris Therapeutics's target upside or downside calculated?

The average target of $16.33 is divided by the recorded price of $1.28, then one is subtracted to produce +1,176%. This does not guarantee a future return.

When was Kalaris Therapeutics's analyst forecast verified?

The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.